Limits...
Abatacept in the treatment of rheumatoid arthritis.

Vital EM, Emery P - Ther Clin Risk Manag (2006)

Bottom Line: Abatacept (CTLA4-Ig) is a new agent which targets T-cell activation, an event which is thought to be critical to the onset and maintenance of rheumatoid arthritis (RA).Safety profile is favorable in combination with DMARDs.The mechanism of action and available evidence of its efficacy and safety are reviewed in this article.

View Article: PubMed Central - PubMed

Affiliation: Academic Unit of Musculoskeletal Disease, University of Leeds, Chapel Allerton Hospital Leeds, UK.

ABSTRACT
Abatacept (CTLA4-Ig) is a new agent which targets T-cell activation, an event which is thought to be critical to the onset and maintenance of rheumatoid arthritis (RA). Abatacept now has substantial evidence from phase III trials for efficacy in patients with RA who have failed to respond to disease-modifying antirheumatic drugs (DMARDs) and antitumor necrosis factor-alpha (TNF-alpha) biologic agents. Safety profile is favorable in combination with DMARDs. The mechanism of action and available evidence of its efficacy and safety are reviewed in this article.

No MeSH data available.


Related in: MedlinePlus

Percentage of patients achieving 50% improvement in mHAQ from baseline on abatacept 10 mg/kg–methotrexate or placebo–methotrexate.Abbreviations: mHAQ, Modified Stanford Health Assessment Questionnaire.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC1936358&req=5

fig4: Percentage of patients achieving 50% improvement in mHAQ from baseline on abatacept 10 mg/kg–methotrexate or placebo–methotrexate.Abbreviations: mHAQ, Modified Stanford Health Assessment Questionnaire.

Mentions: A separate analysis of data from the phase IIb study has shown that improvements in disease activity, pain and physical function occurred by 30 days (Emery et al 2004). The proportion of patients achieving a 50% improvement in the pain visual analog scale (VAS), mHAQ, and ACR50 were compared between treatment arms at time-points from 15 to 360 days. Visual analogue scales for disease activity and pain were significantly better in the abatacept group by 15 days. ACR and mHAQ results are shown in Figures 3 and 4.


Abatacept in the treatment of rheumatoid arthritis.

Vital EM, Emery P - Ther Clin Risk Manag (2006)

Percentage of patients achieving 50% improvement in mHAQ from baseline on abatacept 10 mg/kg–methotrexate or placebo–methotrexate.Abbreviations: mHAQ, Modified Stanford Health Assessment Questionnaire.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC1936358&req=5

fig4: Percentage of patients achieving 50% improvement in mHAQ from baseline on abatacept 10 mg/kg–methotrexate or placebo–methotrexate.Abbreviations: mHAQ, Modified Stanford Health Assessment Questionnaire.
Mentions: A separate analysis of data from the phase IIb study has shown that improvements in disease activity, pain and physical function occurred by 30 days (Emery et al 2004). The proportion of patients achieving a 50% improvement in the pain visual analog scale (VAS), mHAQ, and ACR50 were compared between treatment arms at time-points from 15 to 360 days. Visual analogue scales for disease activity and pain were significantly better in the abatacept group by 15 days. ACR and mHAQ results are shown in Figures 3 and 4.

Bottom Line: Abatacept (CTLA4-Ig) is a new agent which targets T-cell activation, an event which is thought to be critical to the onset and maintenance of rheumatoid arthritis (RA).Safety profile is favorable in combination with DMARDs.The mechanism of action and available evidence of its efficacy and safety are reviewed in this article.

View Article: PubMed Central - PubMed

Affiliation: Academic Unit of Musculoskeletal Disease, University of Leeds, Chapel Allerton Hospital Leeds, UK.

ABSTRACT
Abatacept (CTLA4-Ig) is a new agent which targets T-cell activation, an event which is thought to be critical to the onset and maintenance of rheumatoid arthritis (RA). Abatacept now has substantial evidence from phase III trials for efficacy in patients with RA who have failed to respond to disease-modifying antirheumatic drugs (DMARDs) and antitumor necrosis factor-alpha (TNF-alpha) biologic agents. Safety profile is favorable in combination with DMARDs. The mechanism of action and available evidence of its efficacy and safety are reviewed in this article.

No MeSH data available.


Related in: MedlinePlus